Apert p.Ser252Trp mutation in FGFR2 alters osteogenic potential and gene expression of cranial periosteal cells

Molecular Medicine

Volumn 13, Issue 7-8, 2007, Pages 422-442

  Fanganiello, Roberto D ^a   Sertié, Andréa L ^a   Reis, Eduardo M ^a   Yeh, Erika ^a   Oliveira, Nélio A J ^a   Bueno, Daniela F ^a   Kerkis, Irina ^b   Alonso, Nivaldo ^a   Cavalheiro, Sérgio ^c   Matsushita, Hamilton ^c   Freitas, Renato ^d   Verjovski Almeida, Sergio ^a   Passos Bueno, Maria Rita ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto Butantã   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Centro de Atendimento ao Fissurado   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RNA; SERINE; TRYPTOPHAN;

ACROCEPHALOSYNDACTYLY; ARTICLE; BONE DEVELOPMENT; CELL ADHESION; CELL LINEAGE; CELL PROLIFERATION; CONTROLLED STUDY; CRANIAL SUTURE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PERIOSTEUM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKULL; UNINDEXED SEQUENCE;

ACROCEPHALOSYNDACTYLIA; ADOLESCENT; AMINO ACID SUBSTITUTION; CELL DIFFERENTIATION; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; FEMALE; FIBROBLASTS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; INFANT; MALE; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOGENESIS; PERIOSTEUM; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SERINE; SKULL; TRYPTOPHAN;

EID: 34548492521     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2007-00027.Fanganiello     Document Type: Article

References (31)

1. Cohen MM Jr et al. (1992) Birth prevalence study of the Apert syndrome. Am. J. Med. Genet. 42:655-9.
2. Upton J, Zuker RM (eds) (1991) Clinics in plastic surgery. Vol 18: Apert syndrome. WB Saunders, Philadelphia.
3. Park WJ et al. (1995) Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. Am. J. Hum. Genet. 57:321-8.
4. Slaney SF, et al. (1996) Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. Am. J. Hum. Genet. 58:923-32.
5. Cohen MM Jr. (2000) Syndromes with craniosynostosis. In: Cohen Jr MM, MacLean RE. (eds) Craniosynostosis: Diagnosis, Evaluation, and Management. New York: Oxford University Press. 309-141.
6. Moloney DM et al. (1996) Exclusive paternal origin of new mutations in Apert syndrome. Nat. Genet., 13:48-53.
7. Wilkie AO et al. (1995) Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat. Genet. 9:165-72.
8. Anderson J, Burns HD, Enriquez-Harris P, Wilkie AO, Heath JK. (1998) Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum. Mol. Genet. 7:1475-83.
9. Yu K, Herr AB, Waksman G, Ornitz DM. (2000) Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc. Natl. Acad. Sci. U. S. A. 7:14536-11.
10. Ibrahimi OA, Zhang F, Hrstka SC, Mohammadi M, Linhardt RJ. (2004) Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry. 43:4724-30.
11. Lomri A, Lemonnier J, Hott M, et al. (1998) Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J. Clin. Invest. 101:1310-7.
12. Lemonnier J, Delannoy Ph, Hott M, Lomri A, Modrowski D, Marie PJ. (2000) The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation. Exp. Cell Res. 256:158-67.
13. Mansukhani A, Bellosta P, Sahni M, Basilico C. (2000) Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J. Cell Biol. 149:1297-1308.
14. Lomri A, Lemonnier J, Delannoy P, Marie PJ. (2001) Increased expression of protein kinase Calpha, interleukin-1 alpha, and RhoA guanosine 5′-triphosphatase in osteoblasts expressing the Ser252Trp fibroblast growth factor 2 receptor Apert mutation: identification by analysis of complementary DNA microarray. J. Bone Miner. Res. 16:705-12.
15. Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Basilico C. (2005) Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J. Cell Biol. 168:1065-76.
16. Chen L, Li D, Li C, Engel A, Deng CX. (2005) A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone. 33:169-78. Erratum in: Bone. (2005) 37:876.
17. Wang Y et al. (2005) Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development. 132:3537-48.
18. Hopper RA et al. (2001) Effect of isolation of periosteum and dura on the healing of rabbit calvarial inlay bone grafts. Plast. Reconstr. Surg. 107:454-62
19. Ozerdem OR et al. (2003) Roles of periosteum, dura, and adjacent bone on healing of cranial osteonecrosis. J. Craniofac. Surg.14:371-9.
20. Carinci F et al. (2002) Expression profiles of craniosynostosis-derived fibroblasts. Mol. Med. 8:638-44.
21. Zuk PA et al. (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 7:211-28.
22. Quackenbush J. (2002) Microarray data normalization and transformation. Nat Genet. 32(Supp1.):496-501.
23. Golub TR et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:531-7.
24. Reis EM et al. (2004) Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer. Oncogene. 23:6684-92.
25. van't Veer LJ et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530-6.
26. Takahashi K, Murakami M, Yamanaka S. (2005) Role of the phosphoinositide 3-kinase pathway in mouse embryonic stem (ES) cells. Biochem. Soc. Trans. 33:522-5.
27. Armstrong L et al. (2006) The role of PI3K/AKT, MAPK/ERK and NFkappabeta signaling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum. Mol. Genet. 15:1894-1913.
28. Bodo M et al. (1997) Glycosaminoglycan metabolism and cytokine release in normal and otosclerotic human bone cells interleukin-1 treated. Eur. J. Clin. Invest. 27:36-42.
29. Twigg SR et al. (2004) Mutations of ephrin-B1 (EFNB1), a marker of tissue boundary formation, cause craniofrontonasal syndrome. Proc. Natl. Acad. Sci. U S A. 101:8652-7.
30. Yokote H et al. (2005) Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proc. Natl. Acad. Sci. U. S. A. 102:8866-71.
31. Li C, Scott DA, Hatch E, Tian X, Mansour SL. (2007) Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development. Development. 134:167-76.